Inogen’s share price has performed poorly since I rated the stock a Buy in July 2023, and for good reason. Another round of senior executive changes combined with a questionable acquisition has ...
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial ...
Inogen, Inc. INGN incurred an adjusted loss per share of 2 cents for second-quarter 2025, which was narrower than the adjusted loss per share of 7 cents in the year-ago period and the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback